Eli Lilly's Weight Loss Drug Shows Promising Results in Mid-Stage Trial
The company plans to launch Phase 3 trials for the combination regimen by year-end after mid-stage data showed significant weight reduction.
First reported by Quartz, 2h 04m ahead of the next publisher · who breaks stories first
How it unfolded
Every source in the order it published.
- QuartzEli Lilly's experimental weight loss drug shed 21% of body weight in diabetes trial
- QuartzDas experimentelle Gewichtsverlust-Medikament von Eli Lilly reduzierte das Körpergewicht in einer Diabetes-Studie um 21 %.
- STATSTAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
- CNBCEli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- MarketWatchAdding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
Sources
Every article we clustered into this story. Headlines link to the publisher.
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial CNBC ·
- Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects. MarketWatch
- STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial STAT
- Eli Lilly's experimental weight loss drug shed 21% of body weight in diabetes trial Quartz
- Das experimentelle Gewichtsverlust-Medikament von Eli Lilly reduzierte das Körpergewicht in einer Diabetes-Studie um 21 %. Quartz
In this story
- Eli Lilly
- tirzepatide
- eloralintide